Novelos Therapeutics

die Aktie wurde letztens vom Aktionär empfohlen. Sie befindet sich seit Januar in einem steilen Anstieg. Die Firma hat zwei Medikamente in der pipeline, die mit etwas Glück zu Blockbustern werden könnten.
Hat Jemand weitere Informationen? Könnte sich der Einstieg auf dem jetzigen Niveau, aktuell 0,90 Euro lohnen?
Gruß Gretel

NOV-002, Cancer

NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. In the U.S., Novelos received a "green light" from the FDA for Phase 3 development of NOV-002 for treatment of lung cancer, under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim®. It has been administered to over 5,000 patients, demonstrating clinical efficacy and excellent safety data.

In the U.S.
The Russian preclinical and clinical data have been sufficiently compelling that the United States Food and Drug Administration (FDA) has accepted them as part of the Investigational New Drug Application (IND) that Novelos has filed for NOV-002.

The U.S.-based Phase 1/2 clinical trial of NOV-002 for non-small cell lung cancer (NSCLC) has been completed, with positive results. Forty-four chemotherapy-naive Stage IIIb/IV NSCLC patients (late-stage lung cancer patients who have not received prior chemotherapy) were randomized to one of three groups for six months of treatment:

Group A: NOV-002, administered intravenously (IV) and intramuscularly, in combination with cytotoxic chemotherapy.
Group B: NOV-002, administered IV and subcutaneously (SC), in combination with cytotoxic chemotherapy.
Group C: Cytotoxic chemotherapy alone was administered to this control group.

Based on the trial protocol, the intent-to-treat analysis of the best overall objective tumor response (i.e. complete or partial tumor shrinkage) showed that eleven out of sixteen (69%) NOV-002 treated patients in Group B demonstrated greater than 50% tumor shrinkage versus only five out of fifteen (33%) in the control group (C). This difference was statistically significant (p=0.044 in a stratified analysis). Six out of thirteen (46%) patients in Group A demonstrated an objective response.

Further, NOV-002 treated patients better tolerated cytotoxic chemotherapy as evidenced by their ability to receive more cycles of chemotherapy compared to the control group (C). 100% of patients in Group B and 85% in Group A were able to complete four cycles of chemotherapy, while only 50% of control group patients (C) were able to do so. These differences were statistically significant (p=0.004). In addition, NOV-002 was well tolerated in this patient population, adding to NOV-002’s already extensive safety database.

During the End-of-Phase 2 meeting, the FDA agreed that advancing NOV-002 into a pivotal Phase 3 trial in advanced NSCLC, in combination with first-line chemotherapy, is warranted. In May 2006, Novelos finalized a SPA with the FDA for a single pivotal Phase 3 trial, and obtained Fast Track designation in August 2006.

Novelos\' randomized, open-label, international Phase 3 trial will evaluate NOV-002 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone, in 840 patients with Stage IIIb/IV NSCLC. The trial, with a primary efficacy endpoint of improvement in overall survival, will be conducted across approximately 10 countries and 100 clinical sites. Novelos expects commencing the trial in November 2006, and anticipates reaching full enrollment in the first quarter of 2008.

NOV-002 is also being developed to treat chemotherapy-resistant ovarian cancer. A U.S. Phase 2 trial is ongoing at Mass General Hospital and Dana Farber Cancer Institute.

NOV-002 is also being developed to treat early-stage breast cancer. These patients are often treated with chemotherapy to minimize or avoid surgical intervention. A planned U.S. Phase 2 trial will evaluate the ability of NOV-002 to enhance the effectiveness of such chemotherapy while diminishing dose-limiting side-effects.

NOV-002 is in addition being developed to treat acute radiation injury.

Click below for:
Poster Presentation of NOV-002 Phase 1/2 Lung Cancer Trial

Poster Presentation of NOV-002 Mechanism of Action

In Russia
Numerous clinical studies have been concluded in the Russian Federation over the last decade, and NOV-002 was approved as an adjunct to chemotherapy in the Russian Federation in 1998. The Russian approval was obtained by demonstrating clinical efficacy and excellent safety in 340 patients with various types of cancers, including: non-small cell lung, colorectal, breast, ovarian, pancreatic, etc.

Overall, the studies revealed that NOV-002 could be safely and effectively added to various chemotherapy regimens. The treated patients had a better quality of life and more rapid restoration of hematological and immunological indices. They tolerated the combination therapy better than standard chemotherapy alone, as evidenced by receiving greater number of chemotherapy cycles. Further, in a controlled Russian lung cancer trial, when used in combination with chemotherapy, NOV-002 increased the one year survival rate of patients from 17% to 63%, a result that represents an 80% improvement over the 35% survival rate seen with the current standard of care in the U.S..

NOV-002 also sensitized previously platinum-resistant ovarian cancer patients to chemotherapy in a Russian-based trial. In combination with NOV-002, 80% of the treated women responded favorably to the same chemotherapy that they previously failed.

NOV-205, Hepatitis

NOV-205 is being developed to treat chronic hepatitis C in the U.S. NOV-205 acts as a hepatoprotective agent with immunomodulating and antiinflammatory properties. The FDA accepted Novelos\' Investigational New Drug Application (IND) for NOV-205. The initial U.S.-based Phase 1b trial will evaluate NOV-205 as monotherapy for chronic hepatitis C genotype 1 patients who have failed pegylated interferon plus ribavirin therapy. The trial commenced in September 2006.

NOV-205 is approved for use in the Russian Federation under the trade name Molixan®. Commercialization of NOV-205 is commencing in Russia. Clinical studies in 178 Russian hepatitis patients have demonstrated that NOV-205 is effective and safe. The Russian clinical studies in hepatitis B and C patients showed that after relatively short treatment periods (1 to 2 months) with NOV-205, viral load was undetectable in a high proportion of patients and serum biochemical markers of liver damage were significantly decreased. Overall, more than 700 Russian hepatitis patients have been treated successfully with NOV-205. Preclinical studies also support NOV-205\'s anti-viral and hepatoprotective effects.